A carregar...
Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
BACKGROUND: We evaluated antidrug antibody (ADA) development in patients with chronic plaque psoriasis from three clinical trials of tildrakizumab, a humanized anti‐interleukin‐23p19 monoclonal antibody (P05495, reSURFACE 1 and reSURFACE 2). OBJECTIVES: To determine the effects of immunogenicity on...
Na minha lista:
| Publicado no: | Br J Dermatol |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6972989/ https://ncbi.nlm.nih.gov/pubmed/30916381 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.17918 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|